News and Trends 18 May 2017 Heptares receives €4.5M Milestone for New Migraine Drug Candidate The UK biotech attacking notoriously evasive GPCRs has discovered a small molecule that could be used to treat migraine headaches. Heptares, owned by Sosei and based just outside London, will take home €4.5M ($5M) from Teva for discovering a drug candidate for migraine treatment. The small molecule is an calcitonin gene-related peptide (CGRP) agonist that could relieve patients […] May 18, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2017 Italy is Getting its First-Ever Early Stage Biotech Fund for Tech Transfer AurorA-TT is making plans to raise €50M for what will be the first fund dedicated to investing in tech transfer within the Italian biotech ecosystem. AurorA-TT is a newborn company in Milan with the goal of promoting technology transfer in Italy. To do so, the plan is to raise a €50M fund dedicated to biotech. “There’s […] May 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2017 Danish Biotech Targeting Ion Channels Completes Private Placement The biotech company Saniona has announced the issue of new shares to Swedish and international investors, raising a total of €3.6M. Saniona, a Danish biotech listed on the Nasdaq First North Premier, just completed a private placement that raised €3.6M (SEK 35M) before issue costs. The funds are intended to provide the company with more flexibility […] May 17, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2017 A Spanish Biosimilar of Amgen’s Blockbuster gets Ready for EU Approval Cinfa Biotech announced trial results for a biosimilar of Amgen’s Neulasta, a multi-billion blockbuster to treat chemotherapy-induced neutropenia. Cinfa Biotech is a Spanish company specialized in developing biosimilars. The biotech has announced positive results from the second clinical trial evaluating a biosimilar version of Neulasta (pegfilgrastim), Amgen’s second top-selling drug. It brought the big pharma €4.2Bn in […] May 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2017 Way to Success: What Role does Company Culture Play in Biotech? You’ve surely heard how great company culture is the key to the success of tech giants Google and Facebook. Does it also apply to biotech companies? Company culture is what drives employees to give their best every day for a cause they believe in. It’s what makes the best stay loyal to a firm over […] May 17, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2017 Berlin Biotech Advances its Cancer Drug in a New Trial with Keytruda Noxxon Pharma has teamed up with the NCT in Heidelberg to conduct a Phase I/II trial combining its lead NOX-A12 with checkpoint inhibitor Keytruda. Based in Berlin, Noxxon is yet another biotech looking to bolster the success of checkpoint inhibitors by combining them with its ‘next-generation’ immuno-oncology candidates. The company partnered up with Merck & Co. […] May 16, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2017 German Biotech Clears Phase I with New Gene Therapy for Glaucoma Isarna Therapeutics showed off positive Phase I data for its lead compound ISTH0036 in patients with Glaucoma at the ARVO meeting last week. Isarna Therapeutics from Munich is developing TGF-β specific antisense RNA therapeutics to treat ophthalmic and fibrotic diseases and cancer. Now the company has cleared its first Phase I trial for its lead candidate ISTH0036 in […] May 15, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2017 How to Save Time and Money when Recruiting in the Life Sciences The right hiring choice can bring huge benefits to the growth of a life sciences company. How can you make the best decision while saving time and money? In Europe, a bad hire costs employers an average of almost €60,000, starting with a minimum of €6,000 that rapidly escalates with the seniority of the role […] May 15, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 13 May 2017 Visualizing the Microbiome through Handmade Embroidery Rebecca Harris is a British artist that uses handmade embroidery to visually communicate the huge diversity of microbes that form part of our bodies. Trillions of microbes live on us and inside us. “Microbes are essential for our well-being and development. The microbes stimulate and develop the immune response, and they detoxify harmful carcinogenic compounds in our […] May 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2017 German Biotech Raises €15M to Treat Heart Failure with Non-coding RNA Cardior Pharmaceuticals will use the funds to develop an innovative technology based on non-coding RNAs involved in cardiac remodeling. Founded less than a year ago, Cardior Pharmaceuticals is dedicated to developing a novel technology to predict and treat heart failure. In such a short timeframe, the German biotech has managed to attract some of the best […] May 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2017 Resurrected Proteins could be New Weapon against Crop Viruses Researchers from Spain have succeeded in expressing a 4 billion year-old enzyme in a present-day E. coli. It’s similar enough to the modern version to work, but different enough to dupe viruses. A new way to create virus resistance in crops? In a lab at the University of Granada, Spain, that specializes in reconstructing ancient gene sequences, researchers have […] May 12, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2017 UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval UPDATE (12/05/2017): Newron has received €11.3M as a milestone payment for the approval from its partner, Zambon, which has the rights to commercialise Xadago globally. Originally published on 21/04/2017 Newron, an Italian biotech focused on CNS diseases, is on a roll. The latest win? FDA approval of its Parkinson’s drug, Xadago. Just in time for World […] May 12, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email